Bolwell B J, Fishleder A, Andresen S W, Lichtin A E, Koo A, Yanssens T, Burwell R, Baucco P, Green R
Department of Hematology/Oncology, Cleveland Clinic Foundation, OH 44195.
Bone Marrow Transplant. 1993 Dec;12(6):609-14.
G-CSF and GM-CSF enhance the rate of neutrophil engraftment in autologous bone marrow transplantation (ABMT) without significantly affecting platelet engraftment. Peripheral blood progenitor cells (PBPC) may enhance rates of engraftment of both neutrophils and platelets. We treated 49 patients undergoing ABMT with a course of G-CSF to obtain PBPC and infused these cells post-transplant with G-CSF in an attempt to determine factors which might correlate with enhanced BM engraftment. Forty-nine patients with Hodgkin's disease, non-Hodgkin's lymphoma or breast cancer undergoing unpurged ABMT were studied. G-CSF priming consisted of an outpatient 8 day course of 5 micrograms/kg/day followed by three leukaphereses (on day 5, 7 and 8) to collect PBPC. Patients then received a chemotherapeutic BMT preparative regimen followed by an infusion of PBPC, autologous BM and the reinstitution of G-CSF (16 micrograms/kg/day). BM engraftment was rapid. The median time to achieve 0.5 x 10(9)/l neutrophils was 10 days compared with a historical BMT control patient population receiving the same preparative regimens of 19 days (p = 0.001). Time to achieve a platelet count of 20 x 10(9)/l was 16 days compared with a historical control of 22 days (p = 0.001). Neutrophil engraftment occurred in all patients by day +14. Marrow engraftment correlated with the total number of CD34+ cells infused as well as the total number of mononuclear cells infused but not the total number of CD34+/CD33- cells infused. The amount of total blood volume pheresed significantly correlated with yield of total mononuclear cells. Prior exposure to radiation therapy negatively correlated with progenitor cell yield.(ABSTRACT TRUNCATED AT 250 WORDS)
粒细胞集落刺激因子(G-CSF)和粒细胞-巨噬细胞集落刺激因子(GM-CSF)可提高自体骨髓移植(ABMT)中中性粒细胞的植入率,且对血小板植入无显著影响。外周血祖细胞(PBPC)可能会提高中性粒细胞和血小板的植入率。我们对49例接受ABMT的患者采用一个疗程的G-CSF治疗以获取PBPC,并在移植后将这些细胞与G-CSF一起输注,试图确定可能与增强骨髓植入相关的因素。对49例患有霍奇金病、非霍奇金淋巴瘤或乳腺癌且接受未净化ABMT的患者进行了研究。G-CSF启动治疗包括门诊8天疗程,剂量为5微克/千克/天,随后进行三次白细胞分离术(在第5、7和8天)以采集PBPC。患者随后接受化疗性骨髓移植预处理方案,接着输注PBPC、自体骨髓并重新使用G-CSF(16微克/千克/天)。骨髓植入迅速。达到0.5×10⁹/L中性粒细胞的中位时间为10天,而接受相同预处理方案的历史骨髓移植对照患者群体为19天(p = 0.001)。达到血小板计数20×10⁹/L的时间为16天,而历史对照为22天(p = 0.001)。所有患者在+14天时均出现中性粒细胞植入。骨髓植入与输注的CD34⁺细胞总数以及输注的单核细胞总数相关,但与输注的CD34⁺/CD33⁻细胞总数无关。采集的全血体积量与总单核细胞产量显著相关。既往接受放射治疗与祖细胞产量呈负相关。(摘要截短于250词)